Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycopyrrolate plus neostigmine versus atropine plus neostigmine for reversal of residual neuromuscular blockade in elderly surgical patients
ChiCTR2400094331Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Dec 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of glycopyrronium, neostigmine and atropine in neuromuscular block (NMB), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: heart rate and systemic vascular resistance index. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
glycopyrroniumneostigmineatropine
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on ChiCTR2400094331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094331.